|Articles|March 19, 2020
Episode 52: Cannabinoids
Author(s)Christen Harm, Elaine Quilici
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Advertisement
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma and MedTech Rarely Collide. That Might Be the Biggest Miss in Healthcare
2
Insilico Medicine Enters $120 Million Drug Development Collaboration with Qilu Pharmaceuticals to Advance Cardiometabolic Therapies
3
Seamless Therapeutics Enters $1.12 Billion Global Research Collaboration with Eli Lilly to Develop Therapeutics for Hearing Loss
4
Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
5